|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
GDF11 exhibits tumor suppressive properties in hepatocellular carcinoma cells by restricting clonal expansion and invasion.
|
30890427 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We also demonstrate that CRC-associated human intestinal lymphatic endothelial cells regulate tumor cell growth via growth differentiation factor 11, a soluble matrisome component which in CRC patients was found to be associated with tumor progression.
|
30889293 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In conclusion, GDF11 has a tumor suppressor role in liver cancer, exerts its effects through Smad2/3 signaling and may serve as a novel tumor marker in liver cancer diagnosis.
|
29545874 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
These findings suggested that GDF11 acted as a tumor suppressor gene for pancreatic cancer.
|
30568460 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Intracellular GDF11 retention adds to the concept of tumor-suppressor inactivation and reveals a cell-biological vulnerability for TNBCs lacking therapeutically actionable mutations.
|
29161592 |
2017 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Tumors were classified as high GDF11 expression (n=65) or low GDF11 expression (n=65).
|
17912435 |
2007 |
|
Cachexia
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Given this apparent contradiction in functionality, multiple independent labs sought to discern differences between the two factors and better elucidate age-related changes in circulating GDF11, with most failing to reproduce the initial finding of declining GDF11 levels, and, importantly, all subsequent studies examining the effects of GDF11 on skeletal muscle described an inhibitory effect on regeneration - and that higher doses induce skeletal muscle atrophy and cachexia.
|
31144559 |
2019 |
|
Cachexia
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Here, we find that elevated GDF11 causes signs of cachexia in mice: reduced food intake, body weight, and muscle mass.
|
29425507 |
2018 |
|
Cachexia
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
Although GDF11 treatment can reduce pathological cardiac hypertrophy and associated fibrosis while improving cardiac pump function in pressure overload, high doses of GDF11 cause severe cachexia and death.
|
30571461 |
2018 |
|
Cachexia
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The TGF-β family ligands myostatin, GDF11, and activins are negative regulators of skeletal muscle mass, which have been reported to primarily signal via the ActRIIB receptor on skeletal muscle and thereby induce muscle wasting described as cachexia.
|
29109273 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
This review is focused to present and analyze the recent findings in the emerging research field of GDF11 function in cancer and metabolism, and discusses the controversies surrounding the biology of this atypical growth factor.
|
31681577 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We also demonstrate that CRC-associated human intestinal lymphatic endothelial cells regulate tumor cell growth via growth differentiation factor 11, a soluble matrisome component which in CRC patients was found to be associated with tumor progression.
|
30889293 |
2019 |
|
Myocardial Infarction
|
0.030 |
Biomarker
|
disease |
BEFREE |
We found that GDF11 reduced arrhythmia severity and successfully attenuated myocardial infarction; GDF11 also increased cardiac function after I-R, enhanced HO-1 expression and decreased oxidative damage.
|
30900023 |
2019 |
|
Myocardial Infarction
|
0.030 |
Biomarker
|
disease |
BEFREE |
TERT assists GDF11 to rejuvenate senescent VEGFR2<sup>+</sup>/CD133<sup>+</sup> cells in elderly patients with myocardial infarction.
|
31292540 |
2019 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
High fat diet (HFD)-induced obesity was employed to examine the impacts of Gdf11 gene transfer on HFD-induced adiposity, hyperglycemia, insulin resistance, and hepatic lipid accumulation.
|
31847906 |
2019 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Moreover, no significant differences in circulating concentrations of GDF11 regarding obesity or glycemic status were found.
|
30897065 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
This review is focused to present and analyze the recent findings in the emerging research field of GDF11 function in cancer and metabolism, and discusses the controversies surrounding the biology of this atypical growth factor.
|
31681577 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11.
|
30889293 |
2019 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Growth differentiation factor 11 (GDF11) has an anti-inflammatory effect in the mouse model of atherosclerosis and Alzheimer's disease, but how GDF11 regulates intestinal inflammation during ulcerative colitis (UC) is poorly defined.
|
30188752 |
2018 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Daily intravenous treatment with GDF11-injection can rejuvenate respects of cognition and cerebrovascular changes in AD mice.
|
29480172 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Growth differentiation factor 11 (GDF11), also known as bone morphogenetic protein 11, a member of the transforming growth factor-β superfamily, has been reported to be involved in colorectal cancer.
|
29545874 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The levels of plasma GDF11 in the COPD patients had significant positive correlations with the data of lung function.
|
29731621 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
This study suggests that GDF11 may be a novel target for the diagnosis and treatment of COPD.
|
29680737 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Growth differentiation factor 11 (GDF11), also known as bone morphogenetic protein 11, a member of the transforming growth factor-β superfamily, has been reported to be involved in colorectal cancer.
|
29545874 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Since its discovery in 1999, studies have shown the involvement of GDF11 in normal physiological processes, such as embryonic development and erythropoiesis, as well as in the pathophysiology of aging, cardiovascular disease, diabetes mellitus, and cancer.
|
29113418 |
2017 |